I don't think we should be overly optimistic about
Post# of 15624
(Total Views: 877)
Posted On: 09/28/2017 1:38:56 PM
Re: freedomdreamer #10846
I don't think we should be overly optimistic about news in the next few weeks, I would be satisfied with the next few months.
My rational for saying months is based on the anticipated expansion of the Phase 1 Trial. If the clinicians advised the company to consider such an expansion, that should have come roughly when the initial trial was due to conclude, let's say in June. If patients were added through the month of July and August, allowing 60 days for evaluation, the trial would end in late October. Of course it's possible they added faster than that, and that makes us close to the end of the trial, but I'd rather be conservative.
While I believe that very shortly after the trial is unblinded the company can give us a top line summary of the trial, but for all the detail the data needs to be presented somewhere for peer review, and that takes time. In that the trial now apparently has patients added with skin diseases, a dermatology conference would seem like an appropriate venue, if they'll accept a technical presentation on a cannabis based product.
The good news is that potential partners need not wait for peer review, under confidentiality agreements they can see the data when OWCP does if the company wishes to show it to them. I suspect we'll see some action on this front shortly after the trial is completed.
Gary
My rational for saying months is based on the anticipated expansion of the Phase 1 Trial. If the clinicians advised the company to consider such an expansion, that should have come roughly when the initial trial was due to conclude, let's say in June. If patients were added through the month of July and August, allowing 60 days for evaluation, the trial would end in late October. Of course it's possible they added faster than that, and that makes us close to the end of the trial, but I'd rather be conservative.
While I believe that very shortly after the trial is unblinded the company can give us a top line summary of the trial, but for all the detail the data needs to be presented somewhere for peer review, and that takes time. In that the trial now apparently has patients added with skin diseases, a dermatology conference would seem like an appropriate venue, if they'll accept a technical presentation on a cannabis based product.
The good news is that potential partners need not wait for peer review, under confidentiality agreements they can see the data when OWCP does if the company wishes to show it to them. I suspect we'll see some action on this front shortly after the trial is completed.
Gary
(1)
(0)